PCOS vs PMOS: What Is the Difference?

If you have been diagnosed with PCOS and are suddenly seeing the term PMOS, you may be wondering whether you have a different condition.

You do not.

In 2026, an international consensus process introduced Polyendocrine Metabolic Ovarian Syndrome (PMOS) as the new name for the condition previously known as Polycystic Ovary Syndrome (PCOS). The change reflects a growing understanding that this is not simply an ovarian condition and that the word “polycystic” can be misleading because the ovaries do not contain pathological cysts. [1]

The underlying condition has not suddenly changed. The name is changing to better describe what clinicians and researchers have understood about it for years: PMOS can involve reproductive, hormonal, metabolic, psychological and dermatological features.

So, what is the difference between PCOS and PMOS?

The name changed. The condition did not.

The term Polycystic Ovary Syndrome has been used for decades. But it creates an immediate problem: the word “polycystic” makes it sound as though ovarian cysts are the defining feature.

They are not.

The ovarian appearance associated with PCOS/PMOS generally reflects a greater number of small follicles rather than abnormal cysts. More importantly, ovarian morphology is only one possible diagnostic feature.

The international diagnostic framework has traditionally allowed a diagnosis when two of three major features are present, after other causes have been excluded:

1. Ovulatory dysfunction or irregular menstrual cycles
2. Clinical or biochemical hyperandrogenism
3. Polycystic ovarian morphology on ultrasound, with AMH now also incorporated into the international guideline as an alternative to ultrasound in adults

This means someone can meet diagnostic criteria without having polycystic-appearing ovaries.

The 2026 name-change consensus specifically identified the old name as misleading because it implies pathological ovarian cysts and can obscure the wider endocrine and metabolic features of the condition. [1]

What does PMOS stand for?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome.

Each part of the name points toward a different aspect of the condition.

Polyendocrine

“Polyendocrine” highlights the involvement of hormonal signalling across multiple systems rather than suggesting that the ovaries are acting in isolation.

Hormones involved in PMOS can include androgens, insulin and reproductive hormones, while adrenal and other endocrine pathways can also contribute to the hormonal picture in some people.

This does not mean that every person with PMOS has an adrenal disorder or abnormal cortisol levels. It means the condition is better understood as a complex endocrine disorder rather than simply an ovarian problem.

Metabolic

Metabolic features are an important part of PMOS.

Insulin resistance can occur in people with PMOS, including people who do not have obesity. Altered insulin signalling can interact with ovarian androgen production and other reproductive pathways.

However, insulin resistance is not required for diagnosis.

This distinction matters. PMOS should not become another label that assumes every person has the same metabolic abnormality.

Ovarian

The ovarian component remains important.

PMOS can affect ovulation, follicle development, androgen production and menstrual regularity. Some people also have polycystic ovarian morphology on ultrasound.

But an ovarian ultrasound is only one part of the clinical picture.

Why can your ovaries look normal and you still have PMOS?

This is one of the most important differences to understand.

A normal ovarian ultrasound does not automatically rule out PMOS.

Under the established diagnostic framework, ovarian morphology is only one of the possible diagnostic features. A person can meet the criteria through ovulatory dysfunction and hyperandrogenism without having polycystic ovarian morphology.

For example, someone might experience:

• Irregular or infrequent periods
• Acne or increased facial/body hair
• Elevated testosterone or other androgens
• Evidence of ovulatory dysfunction

If those findings fit the diagnostic criteria and other conditions have been excluded, a normal-looking ultrasound does not necessarily exclude PMOS.

This is why the statement “your ovaries look normal, so you cannot have PCOS” has never been an accurate interpretation of the Rotterdam diagnostic framework.

The 2026 international guideline continues to recognize these different diagnostic pathways. [2]

PCOS vs. PMOS: What actually changed?

The biggest change is how the condition is named and communicated, not the sudden creation of a completely new diagnostic test.

	Traditional PCOS terminology	PMOS terminology
Name	Polycystic Ovary Syndrome	Polyendocrine Metabolic Ovarian Syndrome
Main message	Sounds primarily ovarian	Highlights endocrine, metabolic and ovarian features
“Cysts”	Implied by the name	Removed from the name because they are misleading
Ultrasound	One possible diagnostic feature	Still one possible diagnostic feature
Hormones	Important	Explicitly emphasized by the name
Metabolic health	Recognized in clinical care	Explicitly reflected in the name
Diagnosis	Established diagnostic criteria	Current PMOS guidance continues the existing evidence-based framework during transition
Treatment	Individualized	Individualized, based on symptoms, reproductive goals and metabolic/cardiovascular risk

The important point is that PMOS is not simply “PCOS but with insulin resistance.”

It is the new name for the same condition, chosen because the old name did not adequately represent its complexity.

What happens to the Rotterdam criteria?

The Rotterdam criteria were established in 2003 and broadened the diagnostic framework by recognizing three major features: ovulatory dysfunction, hyperandrogenism and polycystic ovarian morphology.

Two of those three features are generally sufficient for diagnosis after other causes have been excluded. [3]

The 2026 PMOS guideline does not throw this framework away.

Instead, current international guidance continues to use the established diagnostic features while refining how individual features are assessed. In adults, anti-Müllerian hormone (AMH) can be used as an alternative to ultrasound for defining polycystic ovarian morphology when appropriate. [2]

That means there is currently no separate blood test called a “PMOS test.”

There is also no single fasting insulin value, DHEA-S result or ultrasound finding that independently diagnoses PMOS.

Diagnosis remains a clinical process.

What role does insulin play?

Insulin deserves attention because metabolic health is an important part of PMOS, but it should not be presented as the universal root cause.

Insulin resistance means the body’s tissues respond less effectively to insulin. The pancreas may compensate by producing more insulin.

Higher insulin concentrations can interact with ovarian steroid production and contribute to increased androgen levels in some people with PMOS.

This helps explain why metabolic and reproductive features can overlap.

But PMOS is heterogeneous.

Some people have significant metabolic abnormalities. Others have a normal body weight and different metabolic profiles. Some have prominent androgen-related symptoms, while others primarily experience irregular cycles or ovulatory dysfunction.

That variation is one reason personalized assessment matters.

Does PMOS mean treatment is completely different?

No.

The name change does not mean that established treatments suddenly stop working.

Treatment remains individualized according to the person’s symptoms, reproductive goals, metabolic health and other risk factors.

Depending on the individual, clinical management can include lifestyle interventions, menstrual-cycle management, treatments for androgen-related symptoms, fertility treatment when pregnancy is desired, and medications such as metformin when clinically appropriate.

Hormonal contraceptives can still have an important role for some people, particularly for managing irregular menstrual cycles and hyperandrogenic symptoms. They are not simply “symptom masking” and should not be presented as inherently inappropriate.

Likewise, metabolic assessment should not replace reproductive or hormonal assessment.

The modern approach is broader: look at the whole person rather than one symptom or one scan.

What tests might your doctor consider?

There is no universal “PMOS blood panel.”

Depending on your symptoms and medical history, a clinician may consider tests that assess reproductive hormones, androgen excess, glucose metabolism and cardiovascular risk, while also ruling out other conditions that can produce similar symptoms.

Depending on the clinical situation, this may include:

• Total and/or free testosterone
• Sex hormone-binding globulin (SHBG)
• DHEA-S when adrenal androgen excess needs evaluation
• Glucose testing
• HbA1c in appropriate situations
• An oral glucose tolerance test (OGTT), particularly when assessing glycemic risk
• Lipid profile
• Other hormone tests when needed to exclude alternative diagnoses

Fasting insulin is sometimes measured in clinical or research settings, but it is not a standalone diagnostic test for PMOS, and current international guidelines do not recommend treating one insulin measurement as the defining test for the condition.

Your doctor may also consider your menstrual history, symptoms, blood pressure, weight or waist measurements, reproductive goals and family history.

How to prepare for a PMOS appointment

You do not need to arrive with a diagnosis already figured out.

Instead, bring a clear record of what your body has been doing.

1. Track your patterns

Record cycle timing, sleep, energy, mood, cravings, symptoms and other changes you notice.

2. Bring your previous results

If you have previous hormone tests, glucose results, lipid panels or ultrasound reports, keep them together.

3. Look for patterns

A single difficult day rarely explains your health. Patterns over several weeks can give your clinician more useful context.

4. Ask broader questions

Instead of asking only, “Do I have cysts?”, you can ask:

• Could my symptoms fit PMOS?
• Do my menstrual patterns suggest ovulatory dysfunction?
• Should my androgen levels be assessed?
• Should I be screened for glucose or cardiovascular risk?
• Are there other conditions that should be ruled out?

This turns the appointment from a discussion about one ultrasound into a discussion about the whole clinical picture.

Track more than your period

A cycle tracker can tell you when your period starts.

It cannot necessarily tell you what was happening around your energy, sleep, cravings, mood or symptoms during that cycle.

That is where broader symptom tracking can become useful.

With HeyTimi, you can record daily symptoms and patterns alongside your cycle, including energy, mood, sleep and cravings. Over time, those records can help you identify patterns worth discussing with your healthcare professional and prepare a clearer picture of your symptoms.

Your data does not diagnose PMOS.

It gives you better information to bring into the conversation.

Frequently Asked Questions

Is PMOS an official new medical diagnosis replacing PCOS?

PMOS is the internationally agreed new name for the condition previously known as PCOS.

The name-change process was announced in May 2026 following a global consensus process involving patients, healthcare professionals and 56 organizations. A transition period is underway, with the new terminology being incorporated across guidelines, education, research and health systems.

Can you have PMOS if your ovaries look completely normal?

Yes.

Ovarian morphology is not required when the other diagnostic features are sufficient. A person can meet the diagnostic criteria through ovulatory dysfunction and hyperandrogenism without polycystic ovarian morphology. [2]

Is PMOS caused by insulin resistance?

Not necessarily.

Insulin resistance is an important and common metabolic feature of PMOS, but it is not present in every person and is not required for diagnosis.

Does PMOS require an ultrasound?

No.

Ultrasound can be useful in some diagnostic pathways, but it is not universally required. In adults, current international guidance also recognizes AMH as an alternative to ultrasound for defining polycystic ovarian morphology when appropriate. [2]

Is there a special PMOS blood test?

No.

There is no single blood test that confirms PMOS. Diagnosis involves a combination of clinical history, symptoms, laboratory assessment and, when appropriate, ovarian assessment, while excluding other possible causes.

Has treatment changed because of the name change?

The name change itself does not create an entirely new treatment protocol.

The goal is to reinforce comprehensive care across reproductive, endocrine, metabolic, psychological and other relevant features rather than focusing narrowly on the ovaries.

The bottom line

PCOS and PMOS refer to the same underlying condition.

PMOS is the new internationally agreed name because “polycystic ovary syndrome” can make a complex multisystem endocrine and metabolic condition sound like an ovarian cyst disorder.

A normal ultrasound does not automatically rule out PMOS.

Insulin resistance can be important, but it is not universal or required for diagnosis.

And there is no single “PMOS test.”

The most useful shift is not from one label to another. It is from looking at one isolated feature to understanding the full pattern: cycles, ovulation, androgens, metabolic health, symptoms and long-term risk.

That broader picture is what you can take to your healthcare professional.

Medical Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. PMOS/PCOS can present differently from person to person. Always consult a qualified healthcare professional for individual assessment, testing and treatment decisions.

References

[1] Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026.

[2] Monash University. International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome. Updated 2026.

[3] International evidence-based diagnostic framework for PCOS/PMOS, including the Rotterdam criteria and subsequent guideline updates.